一个多式生物边缘风险指数预测了在头部和部状细胞癌中新辅助免疫化学疗法后的复发
Ning Xu1, Defeng Chen2, Junui Yuan3
1Special Clinic, Henan Provincial Stomatological Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Frontiers in immunology
|February 23, 2026
概括
一个新的边际风险指数 (MRIx) 在新辅助免疫化学疗法 (NICT) 后重新定义了头部和部状细胞癌 (HNSCC) 的负边际. 这种生物基础的工具可以提高复发和远程转移的预测,指导个性化的辅助治疗决策.
科学领域:
- 在瘤学瘤学.
- 手术病理学手术病理学
- 免疫治疗是一种免疫疗法.
背景情况:
- 传统的手术边际评估对于用新辅助免疫化学疗法 (NICT) 治疗的头角状细胞癌 (HNSCC) 不足.
- 瘤微环境在NICT后经历了复杂的生物变化,需要一种新的边际评估方法.
研究的目的:
- 开发和验证HNSCC患者接受NICT.治疗的负边缘的新定义.
- 创建一个边际风险指数 (MRIx),包括多模式边际评估,以提高预后准确性.
主要方法:
- 对未经治疗的,HPV阴性HNSCC患者进行NICT和手术的回顾性分析.
- 多模式边缘评估包括组织病理学,瘤负担,分子分析和免疫背景.
- 基于局部区域控制 (LRC) 和远程无转移生存率 (DMFS) 的预后影响的边际风险指数 (MRIx) 的开发和外部验证.
主要成果:
- MRIx将四个领域整合到连续得分中,将患者分为低风险,中等风险和高风险类别.
- 与传统方法相比,MRIx对LRC (C指数=0.72) 和DMFS (C指数=0.75) 的歧视性更强.
- 外部验证证实了MRIx的预后能力,显示了高风险患者的显著风险分层和独立危险比率.
结论:
- 在NICT之后,MRIx为HNSCC.提供了一个基于生物学的工具,可以重新定义NICT后的保证金状态.
- 这个指数准确地识别出患有复发高风险的患者,可能受益于加强治疗.
- 通过识别潜在降级的低风险边缘,MRIx可以实现个性化辅助治疗.
相关概念视频
Cancer
51.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.7K
Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


